Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need

Dr. Xiuning Le highlights real-world data on therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations, emphasizing the need for improved treatments, at ESMO Congress 2024.

Related Content:

Rapid ReadoutsLung Cancer

OncLive’s September Roundup of Key FDA Approvals in Oncology

Patient-Centered Discussions Will Be Critical to Navigate Treatment Selection in EGFR+ NSCLC

FDA Approves Perioperative Nivolumab for Resectable NSCLC